A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. (Q46564278)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Roman LD

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Wilczynski S

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Muderspach LI

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Burnett AF

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

O'Meara A

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Brinkman JA

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Facio G

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Felix JC

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Aldana M

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Weber JS

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

English

0 references

publication date

12 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

558-566

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17631950%20AND%20SRC:MED&resulttype=core&format=json

A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Epidemiologic classification of human papillomavirus types associated with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Heat shock proteins and the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Therapeutic cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Predicted highly expressed genes in archaeal genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Heat shock protein 70-associated peptides elicit specific cancer immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Optimal two-stage designs for phase II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Natural history of cervical squamous intraepithelial lesions: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Human papillomavirus-specific viral types are common in Mexican women affected by cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Mechanisms used by human papillomaviruses to escape the host immune response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038

Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.038